Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Waleed Ghanima, Vickie McDonald, Milica Putnik, Brian Jamieson, Stefan Rune Lethagen

Blood (2023) 142 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2023-190106

Published: 2023

Journal Articles

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 2577.

https://doi.org/10.1182/blood-2023-189908

Published: 2023

Journal Articles

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2023-189224

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Srikanth Nagalla, Shruti Chaturvedi, Moshe Levy, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Brian Jamieson, Debbie Goldschmidt, Elyse Swallow, Ali Greatsinger, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2023-189009

Published: 2023

Journal Articles

Comparative Length of Therapy and Persistence Among Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia (ITP): United States Healthcare Claims and Specialty Pharmacy Prescription Analyses

Scott Kolodny, Brian Jamieson, Thomas Darden

Blood (2022) 140 (Supplement 1): 8414–8415.

https://doi.org/10.1182/blood-2022-168901

Published: 2022

Journal Articles

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Mikhail Davidson, Louise Yu, John Yee

Blood (2022) 140 (Supplement 1): 10889–10890.

https://doi.org/10.1182/blood-2022-169162

Published: 2022

Journal Articles

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Scott Kolodny, Abiola Oladapo, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Priscilla Lopez, Mikhail Davidson, John Yee

Blood (2022) 140 (Supplement 1): 13150–13151.

https://doi.org/10.1182/blood-2022-169369

Published: 2022

Journal Articles

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Hanny Al-Samkari, Debbie Jiang, Terry B. Gernsheimer, Howard A. Liebman, Susie Lee, Chelsea Bernheisel, Scott Kolodny, Matthew Wojdyla, Michael Vredenburg, Brian Jamieson, Adam Cuker

Blood (2021) 138 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2021-151321

Published: 2021

Journal Articles

Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia

Rachael F. Grace, Xiaoqiang Xue, Brian Jamieson

Blood (2021) 138 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2021-144873

Published: 2021

Journal Articles

Further Characterization of Thromboembolic Events and Association with Platelet Count Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

Caroline I. Piatek, Brian Jamieson, Scott Kolodny

Blood (2021) 138 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2021-150897

Published: 2021

Journal Articles

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Wei Tian, PhD, Brian Jamieson, MDBA

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-141290

Published: 2020

Journal Articles

Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study

Shivi Jain, MDMBBS, Matthew Wojdyla, PharmD, Michael Vredenburg, PhD, Brian Jamieson, MDBA, Terry B. Gernsheimer, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142764

Published: 2020

Journal Articles

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag

Michael D Tarantino, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Kashyap B Patel, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142788

Published: 2020

Journal Articles

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Morey Blinder, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Keith R McCrae, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136585

Published: 2020

Journal Articles

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

Caroline I. Piatek, MD, Brian Jamieson, MDBA, Michael Vredenburg, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-141273

Published: 2020

NARROW

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Comparative Length of Therapy and Persistence Among Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia (ITP): United States Healthcare Claims and Specialty Pharmacy Prescription Analyses

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia

Further Characterization of Thromboembolic Events and Association with Platelet Count Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only